About Synapticure
Synapticure launched in early 2022 to serve individuals living with ALS, and we continue to expand our care for additional neurodegenerative diseases including Parkinson’s Disease, Huntington’s, Alzheimer’s and other Dementias. We are backed by Google Ventures, Optum Ventures and other top healthcare investors.Synapticure aims to give all patients living with neurodegenerative disease access to the best care while fueling the advancement of personalized treatments. We do so by creating a guided journey for each patient, their caregivers, and family that educates and empowers while navigating the complex challenges facing patients and facilitating access to critical tests and leading experts. With our patients’ consent, their de-identified data is then used to both inform personalized treatments for patients today and to speed the development of new targeted therapies. Synapticure serves patients in all 50 states and the District of Columbia.Over the next year we’ll be growing quickly to serve thousands of individuals and their families per year; to achieve ...